Ikaria
Ikaria is a critical care therapeutics company founded in 2005 and headquartered in Hampton, New Jersey, that develops innovative inhaled therapeutics and interventions for critically ill patients in the global inhaled nitric oxide market.
- Company typePrivate
- Founded2005
- HeadquartersHampton, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Ikaria firmographics
Firmographics- Name
- Ikaria
- Website
- https://ikaria.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Closed
- Headcount range
- 501–1,000 employees
- Short description
- Ikaria is a critical care therapeutics company founded in 2005 and headquartered in Hampton, New Jersey, that develops innovative inhaled therapeutics and interventions for critically ill patients in the global inhaled nitric oxide market.
- Ownership category
- akta.pro rank
Ikaria industry classification
Industry- Product category
- Critical Care Pharmaceuticals
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Critical Care / ICU Pulmonology (Intensivist Services) (HLAKANAH)
- akta.pro secondary industry
- Noninvasive Ventilation Interfaces & Consumables (Masks, Tubing, Humidifiers, Filters) (HLAHAGAG)
Keywords
Where Ikaria is headquartered
LocationHeadquarters
- HQ city
- Hampton
- HQ country
- United States
- HQ region
- North America
Markets served
Ikaria business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales
Ikaria product offering
Product offeringCore offering
Ikaria is a critical care pharmaceutical firm that develops and commercializes innovative therapeutics, most notably inhaled nitric oxide (iNO), for use in intensive care settings such as neonatal respiratory care and cardiac surgery. The company focuses on meeting the significant medical needs of critically ill patients through proprietary drug-device combination therapies delivered to hospitals and specialty care centers.
Differentiator
Problem solved
Functional benefit
Products and services
- Inhaled Nitric Oxide (iNO) Therapeutic
Companies that use Ikaria
Customer profileIdeal customer profiles1 record
Ikaria technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Ikaria partnerships and signals
Strategic signalScale indicators1 record
Ikaria competitors and assessment
Company assessmentDirect peers
- Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company that historically owned/operated the inhaled nitric oxide franchise (INOmax) acquired from Ikaria, making it the most directly comparable peer in critical care respiratory therapeutics.
- Aires Pharmaceuticals: Specialty pharma focused on pulmonary arterial hypertension and critical care respiratory therapies — a focused peer to Ikaria in hospital-administered respiratory pharmaceuticals.
- Bellerophon Therapeutics: Clinical-stage therapeutics company developing INOpulse inhaled nitric oxide for pulmonary hypertension and cardiopulmonary diseases — directly comparable in mechanism, delivery platform, and critical care respiratory indications.
- Vero Biotech: Developer of next-generation portable nitric oxide delivery systems for critical care, directly competing with Ikaria's legacy iNO delivery platform on mechanism and target customers (NICU/ICU).
Broad incumbents
- Gilead Sciences: Large biopharma with a respiratory/critical care portfolio and significant hospital-channel infrastructure, broadly comparable as a large incumbent in specialty/serious-disease therapeutics.
- Actelion Pharmaceuticals: Established pulmonary hypertension and critical care therapeutics leader (acquired by J&J), comparable in its specialty respiratory franchise and hospital-channel commercialization model.
- United Therapeutics: Commercial-stage specialty pharma with a pulmonary hypertension and critical care portfolio (including prostacyclin and inhaled therapies), broadly comparable in respiratory/critical care therapeutics and target prescribers.
Market position
Customer concentration
Ikaria social profiles
Digital presenceIkaria financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ikaria leadership team
Management profileNumber of profiles
Ikaria funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ikaria M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ikaria
What does Ikaria do?
Ikaria is a critical care pharmaceutical firm that develops and commercializes innovative therapeutics, most notably inhaled nitric oxide (iNO), for use in intensive care settings such as neonatal respiratory care and cardiac surgery. The company focuses on meeting the significant medical needs of critically ill patients through proprietary drug-device combination therapies delivered to hospitals and specialty care centers.
When was Ikaria founded?
Ikaria was founded in 2005. It employs 501 to 1,000 people.
Where is Ikaria based?
Ikaria is headquartered in Hampton, United States, in the North America region.
Who are Ikaria's main competitors?
Direct peers on record are Mallinckrodt Pharmaceuticals, Aires Pharmaceuticals, Bellerophon Therapeutics and Vero Biotech. Broad incumbents are Gilead Sciences, Actelion Pharmaceuticals and United Therapeutics.
Does Ikaria have an API?
No public API is recorded for Ikaria.
What industry is Ikaria in?
Ikaria's product category is Critical Care Pharmaceuticals. Its primary akta.pro industry code is HLAKANAH, Critical Care / ICU Pulmonology (Intensivist Services), with a secondary code of HLAHAGAG, Noninvasive Ventilation Interfaces & Consumables (Masks, Tubing, Humidifiers, Filters). Its NAICS code is 339112 and its SIC code is 3841.